These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24105097)

  • 1. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
    Hesse U; Godman B; Petzold M; Martin A; Malmström RE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
    Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
    Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries.
    Bucsics A; Godman B; Burkhardt T; Schmitzer M; Malmström RE
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):809-19. PubMed ID: 23252361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?
    Bennie M; Bishop I; Godman B; Campbell S; Miranda J; Finlayson AE; Gustafsson LL
    Qual Prim Care; 2013; 21(1):7-15. PubMed ID: 23735629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
    Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
    J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future.
    Vončina L; Strizrep T; Godman B; Bennie M; Bishop I; Campbell S; Vlahović-Palčevski V; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):469-79. PubMed ID: 21831028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.
    Bennie M; Bishop I; Godman B; Barbui C; Raschi E; Campbell S; Miranda J; Gustafsson LL
    Int J Clin Pract; 2013 Feb; 67(2):170-80. PubMed ID: 23305478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries.
    Godman B; Bucsics A; Burkhardt T; Schmitzer M; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):199-207. PubMed ID: 20384566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.
    Martin A; Godman B; Miranda J; Tilstone J; Saleem N; Olsson E; Acosta A; Restrepo L; Bennie M
    J Comp Eff Res; 2014 Jan; 3(1):41-51. PubMed ID: 24345256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications.
    Moon JC; Godman B; Petzold M; Alvarez-Madrazo S; Bennett K; Bishop I; Bucsics A; Hesse U; Martin A; Simoens S; Zara C; Malmström RE
    Front Pharmacol; 2014; 5():219. PubMed ID: 25339902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies.
    Selmer C; Lamberts M; Kristensen SL; von Kappelgaard LM; Køber L; Gislason GH; Torp-Pedersen C
    Pharmacoepidemiol Drug Saf; 2014 Dec; 23(12):1281-7. PubMed ID: 24962821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design.
    Baker A; Chen LC; Elliott RA; Godman B
    BMC Health Serv Res; 2015 Sep; 15():367. PubMed ID: 26359265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions.
    Markovic-Pekovic V; Skrbić R; Godman B; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):661-71. PubMed ID: 23186404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period.
    Almadfaa RO; Wigle PR; Hincapie AL; Guo JJ
    Int J Cardiol; 2023 Jan; 370():412-418. PubMed ID: 36306953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
    Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan.
    Huang SH; Hsu CN; Yu SH; Cham TM
    BMC Public Health; 2012 May; 12():288. PubMed ID: 22521158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.
    Coma A; Zara C; Godman B; Agustí A; Diogène E; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):569-81. PubMed ID: 19941434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
    Eworuke E; Shinde M; Hou L; Paterson MJ; Jensen PB; Maro JC; Rai A; Scarnecchia D; Pennap D; Woronow D; Ghosh RE; Welburn S; Pottegard A; Platt RW; Lee H; Bradley MC
    BMJ Open; 2023 Apr; 13(4):e070985. PubMed ID: 37068898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.